ãã°ã€ã³ã§çµç¹ã»å¥çŽäŸ¡æ Œãã芧ãã ããã
ãµã€ãºãéžæããŠãã ãã
衚瀺ã倿Žãã
ãã®ååã«ã€ããŠ
å®éšåŒïŒãã«è¡šèšæ³ïŒ:
C18H18F2N2O6S2
CASçªå·:
ååé:
460.47
UNSPSC Code:
12352200
NACRES:
NA.51
MDL number:
Assay:
≥99% (HPLC)
Form:
powder
Storage condition:
OK to freeze, protect from light
ãã¯ãã«ã«ãµãŒãã¹
ãå°ãã®ããšãããã°ãçµéšè±å¯ãªãã¯ãã«ã«ãµãŒãã¹ããŒã ãã客æ§ããµããŒãããŸãã
ãæäŒãããŸãQuality Segment
assay
≥99% (HPLC)
form
powder
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, protect from light
color
white
solubility
DMSO: 50 mg/mL
shipped in
ambient
storage temp.
2-8°C
SMILES string
FC(C=CC=C1F)=C1S(N2CCN(S(C3=CC4=C(OCCO4)C=C3)(=O)=O)CC2)(=O)=O
InChI
1S/C18H18F2N2O6S2/c19-14-2-1-3-15(20)18(14)30(25,26)22-8-6-21(7-9-22)29(23,24)13-4-5-16-17(12-13)28-11-10-27-16/h1-5,12H,6-11H2
InChI key
SHWNKRPMUBFWKE-UHFFFAOYSA-N
General description
A cell-permeable diarylsulfonamide (DASA) compound that acts as a potent and selective activator of tumor-specific M2 isozyme of pyruvate kinase (PKM2; AC50 = 65 nM). Pretreatment of A549 (adenocarcinomic human alveolar basal epithelial cells) with DASA-10 (~10 µM) prevents hydrogen peroxide, diamide, and hypoxia-induced inactivation of PKM2. DASA treatment is shown to cause a diminution in cellular glutathione levels, and higher oxidative stress-induced cell death.
Packaging
Packaged under inert gas
Preparation Note
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Other Notes
Anastasiou, D., et al. 2011. Science334, 1278.
Boxer, M.B., et al. 2010. J. Med. Chem.53, 1048.
Boxer, M.B., et al. 2010. J. Med. Chem.53, 1048.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
ä¿ç®¡åé¡
11 - Combustible Solids
WGK
WGK 3
åŒç«ç¹ (F)
Not applicable
åŒç«ç¹ïŒÂ°CïŒ
Not applicable
ææ°ããŒãžã§ã³ã®ãããããéžæããŠãã ããïŒ
以åãã®è£œåãè³Œå ¥ããã ããããšãããå Žå
ææžã©ã€ãã©ãªã§ãæè¿è³Œå ¥ãã補åã®ææžãæ€çŽ¢ã§ããŸãã